- In August 2024, Adaptive Biotechnologies Corporation announced that its diagnostic product clonoSEQ received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU), marking a significant regulatory milestone for diagnosing and monitoring blood cancers
- In June 2024, Amgen revealed that the U.S. Food and Drug Administration (FDA) approved BLINCYTO (blinatumomab) for treating adult and pediatric patients (one month or older) with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, irrespective of measurable residual disease (MRD) status
- In March 2024, Bristol Myers Squibb announced FDA accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor
- In January 2024, Fortis Healthcare launched a specialized institute for blood cancer treatment. The institute introduced CAR-T cell therapy across its Bone Marrow Transplant centers in cities such as Mohali, Delhi, Gurgaon, Noida, Mumbai, and Bangalore
- In June 2021, Jazz Pharmaceuticals received FDA approval for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as part of a multi-agent chemotherapy regimen to treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients aged one month and older who are hypersensitive to E. coli-derived asparaginase
